Upgrade to SI Premium - Free Trial

Regeneron (REGN) Tops Expectations Across Product Line, PT To $410 At Baird

February 7, 2019 6:29 AM
Baird analyst, Brian Skorney, reiterated his Neutral rating on shares of Regeneron Pharma (NASDAQ: REGN) but raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles